Premenstrual Syndrome and Dysphoric Disorder Management

Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) are cyclical disorders of the menstrual cycle characterised by a constellation of physical, emotional and behavioural symptoms that emerge in the luteal phase and resolve with menstruation. While PMS affects up to half of menstruating women, PMDD represents a more severe subset, marked by debilitating mood disturbances, marked irritability, anxiety and functional impairment. Management typically combines lifestyle modification—regular exercise, balanced nutrition, stress reduction—and psychosocial interventions such as cognitive–behavioural therapy to build resilience and coping strategies. Pharmacotherapy remains central: selective serotonin reuptake inhibitors administered continuously or during the luteal phase offer rapid symptom relief. Hormonal approaches include combined oral contraceptives formulated with drospirenone or the use of gonadotropin-releasing hormone agonists in refractory cases. Emerging treatments target neurosteroid pathways: restoration of allopregnanolone balance via synthetic analogues or GABA-A receptor modulators holds promise for women who respond poorly to current regimens. Nutritional strategies informed by cyclical metabolomic profiling and integrative care models that address sleep, circadian health and psychosocial risk are refining personalised treatment. Improved diagnostic recognition, attention to comorbidities such as depression and suicidality, and a multidisciplinary approach are key to optimising quality of life and reducing the public health burden worldwide.

Research from Nature Portfolio

Recent studies have shown that cyclical fluctuations in hormones drive rhythmic changes in nutrient-related metabolites, with the luteal phase marked by reduced amino acids and lipid species. Metabolomic and lipidomic profiling across menstrual phases suggests windows of vulnerability to PMS and PMDD that may be amenable to targeted nutritional interventions. Findings point to altered glutathione metabolism, neurotransmitter precursor rhythms and vitamin D metabolites, laying a biochemical foundation for phase-specific dietary strategies to mitigate symptom severity.

Premenstrual Syndrome and Dysphoric Disorder Management publication trend

The graph below shows the total number of articles in premenstrual syndrome and dysphoric disorder management across all publications each year (not limited to Nature Index journals).

Technical terms

Luteal phase: The post-ovulatory segment of the menstrual cycle during which progesterone levels peak and premenstrual symptoms emerge.

Selective serotonin reuptake inhibitors (SSRIs): A class of antidepressants that increase synaptic serotonin, commonly used to alleviate mood and behavioural symptoms of PMS and PMDD.

Allopregnanolone: A neurosteroid metabolite of progesterone that modulates GABA-A receptors and influences mood and anxiety in premenstrual disorders.

Neurosteroid: A steroid synthesized in the brain that rapidly alters neuronal excitability through modulation of neurotransmitter receptors.

GABA-A receptor complex: An ion-channel receptor for the inhibitory neurotransmitter γ-aminobutyric acid, implicated in the mood effects of neurosteroids and targeted by emerging treatments.

References

1. Menstrual cycle rhythmicity: metabolic patterns in healthy women. Scientific Reports (2018).
2. Steroid Hormone Sensitivity in Reproductive Mood Disorders: On the Role of the GABAA Receptor Complex and Stress During Hormonal Transitions. Frontiers in Medicine (2021).
3. Suicidality in women with Premenstrual Dysphoric Disorder: a systematic literature review. Archives of Women's Mental Health (2020).
4. Women’s experiences of receiving a diagnosis of premenstrual dysphoric disorder: a qualitative investigation. BMC Women's Health (2020).